Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Wohl, P; Krusinová, E; Hill, M; Kratochvílová, S; Zídková, K; Kopeckı, J; Neskudla, T; Pravenec, M; Klementová, M; Vrbíková, J; Wohl, P; Mlejnek, P; Pelikánová, T.
Effect of telmisartan on selected adipokines, insulin sensitivity, and substrate utilization during insulin-stimulated conditions in patients with metabolic syndrome and impaired fasting glucose.
Eur J Endocrinol. 2010; 163(4): 573-583.
Doi: 10.1530/EJE-10-0436
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Svehlikova Eva
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Objective: Telmisartan improves glucose and lipid metabolism in rodents. This study evaluated the effect of telmisartan on insulin sensitivity, substrate utilization, selected plasma adipokines and their expressions in subcutaneous adipose tissue (SAT) in metabolic syndrome. Design and methods: Twelve patients with impaired fasting glucose completed the double-blind, randomized, crossover trial. Patients received telmisartan (160 mg/day) or placebo for 3 weeks and vice versa with a 2-week washout period. At the end of each period, a hyperinsulinemic euglycemic clamp (HEC) combined with indirect calorimetry was performed. During HEC (0, 30, and 120 min), plasma levels of adipokines were measured and a needle biopsy (0 and 30 min) of SAT was performed. Results: Fasting plasma glucose was lower after telmisartan compared with placebo (P < 0.05). There were no differences in insulin sensitivity and substrate utilization. We found no differences in basal plasma adiponectin, resistin and tumour necrosis factor alpha (TNF alpha), but an increase was found in basal leptin, after telmisartan treatment. Insulin-stimulated plasma adiponectin (P < 0.05), leptin and resistin (P < 0.001) were increased, whereas TNF alpha was decreased (P < 0.05) after telmisartan treatment. Expression of resistin, but not adiponectin, TNF alpha and leptin was increased after telmisartan treatment. Conclusions: Despite the decrease in fasting plasma glucose, telmisartan does not improve insulin sensitivity and substrate utilization. Telmisartan increases plasma leptin as well as insulin-stimulated plasma adiponectin, leptin and resistin, and decreases plasma TNF alpha during HEC. Changes in plasma adipokines cannot be explained by their expressions in SAT. The changes in plasma adipokines might be involved in the metabolic effects of telmisartan in metabolic syndrome.
- Find related publications in this database (using NLM MeSH Indexing)
- Adipokines - blood
- Adult -
- Angiotensin-Converting Enzyme Inhibitors - therapeutic use
- Benzimidazoles - therapeutic use
- Benzoates - therapeutic use
- Blood Glucose - drug effects
- Glucose Clamp Technique -
- Glucose Intolerance - blood
- Humans -
- Hypoglycemic Agents - therapeutic use
- Insulin - therapeutic use
- Insulin Resistance - physiology
- Male -
- Metabolic Syndrome X - blood
- Middle Aged -